Literature DB >> 12002379

Histopathological approach to patterns of interstitial pneumonia in patient with connective tissue disorders.

Andrew G Nicholson1, Thomas V Colby, Athol U Wells.   

Abstract

It is well established that some patients with connective tissue disorders will suffer from pulmonary disease at some stage in their disease progression. This article concentrates on the interstitial pneumonias, seen in association with most types of connective tissue disorder, particularly in the ligh of non-specific interstitial pneumonia (NSIP) being recognised as a distinct histological pattern. Most published articles on this subject precede recognition of NSIP and, as such, the relative incidence of patterns of interstitial pneumonia, as defined by the International Consensus Classification Committee for Interstitial Lung Disease (ICCILD), as well as the clinical and prognostic significance of these patterns is undergoing further scrutiny. In this review, the recognised histological patterns, namely usual interstitial pneumonia (UIP), non-specific interstitial pneumonia (NSIP), diffuse alveolar damage (DAD), organising pneumonia (OP), reactive pulmonary lymphoid hyperplasia, desquamative interstitial pneumonia (DIP) and respiratory bronchiolitis-associated interstitial lung disease (RBILD) are reviewed systematically in relation to the various subgroups of connective tissue disorders. As yet, there are few published studies, but current evidence suggests that many cases previously classified as fibrosing alveolitis are likely to show a pattern of NSIP rather than UIP, particularly in relation to systemic sclerosis. The histological pattern of usual interstitial pneumonia, the most frequently seen pattern in biopsies from patients with idiopathic pulmonary fibrosis/cryptogenic fibrosing alveolitis, appears to be comparatively rare. Furthermore, any biopsy showing a combination of histological patterns, a pattern of non-specific interstitial pneumonia or a pattern of lymphoid interstitial pneumonia/follicular bronchiolitis should be thoroughly investigated for a background connective tissue disorder, if previously unsuspected. Finally, the recently published prognostic data relating to these histological patterns in idiopathic disease should not be extrapolated to patients with connective tissue disorders.

Entities:  

Mesh:

Year:  2002        PMID: 12002379

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN: 1124-0490            Impact factor:   0.670


  12 in total

1.  Lower-lobe shrinkage relative to total lung volume in collagen vascular diseases.

Authors:  M Watanabe; T Igishi; N Burioka; J Kurai; Y Fukuoka; K Kato; A Yamasaki; Y Hasegawa; R Okazaki; E Shimizu
Journal:  Radiol Med       Date:  2010-06-23       Impact factor: 3.469

Review 2.  Inflammation-associated remodelling and fibrosis in the lung - a process and an end point.

Authors:  William A H Wallace; Paul M Fitch; A John Simpson; Sarah E M Howie
Journal:  Int J Exp Pathol       Date:  2007-04       Impact factor: 1.925

3.  Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1.

Authors:  Robert Eferl; Peter Hasselblatt; Martina Rath; Helmut Popper; Rainer Zenz; Vukoslav Komnenovic; Maria-Helena Idarraga; Lukas Kenner; Erwin F Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-18       Impact factor: 11.205

4.  Comparison of gene expression profiling between lung fibrotic and emphysematous tissues sampled from patients with combined pulmonary fibrosis and emphysema.

Authors:  Masayuki Hanaoka; Michiko Ito; Yunden Droma; Atsuhito Ushiki; Yoshiaki Kitaguchi; Masanori Yasuo; Keishi Kubo
Journal:  Fibrogenesis Tissue Repair       Date:  2012-10-01

5.  Combined obstructive airflow limitation associated with interstitial lung diseases (O-ILD): the bad phenotype ?

Authors:  Julien Guiot; Monique Henket; Anne-Noëlle Frix; Fanny Gester; Marie Thys; Laurie Giltay; Colin Desir; Catherine Moermans; Makon-Sébastien Njock; Paul Meunier; Jean-Louis Corhay; Renaud Louis
Journal:  Respir Res       Date:  2022-04-11

6.  Vitamin D3 alleviates cigarette smoke extract-mediated epithelial-mesenchymal transition and fibrogenesis by upregulating CC16 expression in bronchial epithelial cells.

Authors:  Yajun Mao; Hong Feng
Journal:  Exp Ther Med       Date:  2022-03-29       Impact factor: 2.447

7.  Lung fibrosis in autoimmune diseases and hypersensitivity: how to separate these from idiopathic pulmonary fibrosis.

Authors:  Helmut Popper; Elvira Stacher-Priehse; Luka Brcic; Andreas Nerlich
Journal:  Rheumatol Int       Date:  2021-10-04       Impact factor: 3.580

Review 8.  Usual interstitial pneumonia-pattern fibrosis in surgical lung biopsies. Clinical, radiological and histopathological clues to aetiology.

Authors:  Maxwell Smith; Mercedes Dalurzo; Prasad Panse; James Parish; Kevin Leslie
Journal:  J Clin Pathol       Date:  2013-05-23       Impact factor: 3.411

9.  Emphysematous change with scleroderma-associated interstitial lung disease: the potential contribution of vasculopathy?

Authors:  Hideaki Yamakawa; Tamiko Takemura; Tae Iwasawa; Yumie Yamanaka; Satoshi Ikeda; Akimasa Sekine; Hideya Kitamura; Tomohisa Baba; Shinichiro Iso; Koji Okudela; Kazuyoshi Kuwano; Takashi Ogura
Journal:  BMC Pulm Med       Date:  2018-01-30       Impact factor: 3.317

10.  Clinical significance of thyroid hormone and antibodies in patients with idiopathic interstitial pneumonia.

Authors:  Yuki Sato; Yoshinori Tanino; Takefumi Nikaido; Ryuichi Togawa; Takaya Kawamata; Xintao Wang; Naoko Fukuhara; Hikaru Tomita; Mikako Saito; Natsumi Watanabe; Mami Rikimaru; Takashi Umeda; Julia Morimoto; Tatsuhiko Koizumi; Yasuhito Suzuki; Kenichiro Hirai; Manabu Uematsu; Hiroyuki Minemura; Atsuro Fukuhara; Suguru Sato; Junpei Saito; Kenya Kanazawa; Yoko Shibata
Journal:  J Thorac Dis       Date:  2020-03       Impact factor: 3.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.